Rein Therapeutics Inc.
- Open
- 0.88
- Day high
- 0.91
- Day low
- 0.85
- Prev close
- 0.86
- Volume
- 175K
- Mkt cap
- $67M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.8
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $75K over the last 3 months (5 open-market buys, 0 sales)
- 🏛Institutions accumulating (13F)
Rein Therapeutics Inc. (RNTX) is a Healthcare company listed on NASDAQ. The stock is down 39% over the past year. Over the trailing 3 months, insiders filed 5 open-market buys and 0 sales (SEC Form 4).
Rein Therapeutics Inc. (RNTX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RNTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | $-0.49 | $-0.19 | +61.2% | — | — |
| Mar 26, 2026 | $-0.24 | $-1.22 | -408.3% | — | — |
| Nov 14, 2025 | $-0.24 | $-0.21 | +12.5% | — | — |
| Aug 14, 2025 | $-0.22 | $-0.28 | -27.3% | — | — |
| Apr 7, 2025 | $-0.14 | $-0.26 | -85.7% | — | — |
| Dec 31, 2024 | $-0.46 | $-1.89 | -310.7% | — | — |
| Aug 14, 2024 | $-0.25 | $-0.45 | -80.0% | — | — |
| Mar 31, 2024 | $-0.14 | $-0.86 | -512.0% | — | — |
| Dec 31, 2023 | $-0.16 | $-1.54 | -840.0% | — | — |
| Sep 30, 2023 | $-0.20 | $-0.40 | -101.2% | — | — |
| Jun 30, 2023 | $-0.40 | $-0.39 | +1.6% | — | — |
RNTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 28, 2026 | VON RICKENBACH JOSEF Hdirector | Buy | 23,190 | $1.06 |
| May 28, 2026 | VON RICKENBACH JOSEF Hdirector | Buy | 15,950 | $1.05 |
| May 28, 2026 | VON RICKENBACH JOSEF Hdirector | Buy | 3,420 | $1.04 |
| May 28, 2026 | VON RICKENBACH JOSEF Hdirector | Buy | 4,500 | $1.07 |
| May 13, 2026 | WINDSOR JAMES BRIANdirector, officer: See Remarks | Buy | 25,000 | $1.00 |
| May 13, 2026 | WINDSOR JAMES BRIANdirector, officer: See Remarks | Grant | 150,000 | $1.17 |
| Nov 18, 2025 | Voss Capital, LP10 percent owner | Buy | 104,183 | $1.22 |
| Oct 28, 2025 | Voss Capital, LP10 percent owner | Buy | 4,840 | $1.37 |
| Oct 28, 2025 | Voss Capital, LP10 percent owner | Buy | 178,392 | $1.39 |
| Oct 28, 2025 | Voss Capital, LP10 percent owner | Buy | 30,176 | $1.39 |
| Oct 28, 2025 | Voss Capital, LP10 percent owner | Buy | 92,642 | $1.37 |
| Jul 23, 2025 | Musso Alan Adirector | Grant | 17,500 | $1.55 |
| Jul 23, 2025 | Aivado Manueldirector | Grant | 17,500 | $1.55 |
| Jul 23, 2025 | Fairey Williamdirector | Grant | 17,500 | $1.55 |
| Jul 23, 2025 | Ambros Reinhard J.director | Grant | 17,500 | $1.55 |
Source: RNTX SEC Form 4 filings, latest May 28, 2026. For informational purposes only — not investment advice.
See the full RNTX insider & 13F page →Rein Therapeutics Inc. company profile
Overview
Rein Therapeutics Inc. (NASDAQ:RNTX) is a clinical-stage biopharmaceutical company founded in 2001 by a team of scientists including Gregory L. Verdine, Rosana Kapeller, and Loren David Walensky. Based in Austin, Texas, the company went public in June 2017 and focuses on developing novel therapeutic approaches for treating cancer and other diseases. Rein Therapeutics represents the growing field of precision oncology, where treatments are designed to target specific molecular pathways involved in cancer development and progression.
Business
Rein Therapeutics operates in the biopharmaceutical industry, specifically focusing on oncology drug development. The company's core expertise lies in developing cell-permeating peptides, which are specially designed protein fragments that can penetrate cell membranes to reach targets inside cancer cells that traditional drugs cannot access effectively. The company's lead product candidate is ALRN-6924, a revolutionary therapeutic approach that targets one of the most fundamental mechanisms of cancer development. To understand this drug's significance, it's important to know about p53, often called the "guardian of the genome." The p53 protein normally acts as a tumor suppressor, detecting damaged DNA in cells and either repairing the damage or triggering cell death to prevent cancer formation. However, in many cancers, this protective mechanism is disrupted. ALRN-6924 works by targeting two proteins called MDM2 and MDMX, which act as suppressors of p53. In healthy cells, these proteins keep p53 activity in check, but in cancer cells, they often become overactive, essentially "silencing" p53 and allowing tumors to grow unchecked. ALRN-6924 disrupts the interaction between these suppressor proteins and p53, effectively "reactivating" the tumor suppression function in cancers where p53 remains functional (called wild-type p53 cancers). This approach represents a significant advancement because approximately 50% of all human cancers retain functional p53, making them potential candidates for this type of therapy. Unlike traditional chemotherapy that broadly damages both healthy and cancerous cells, ALRN-6924 is designed to selectively restore natural tumor suppression mechanisms.
Revenue model
As a clinical-stage biopharmaceutical company, Rein Therapeutics currently generates no revenue from product sales, as evidenced by zero revenue across all reported periods. The company operates on a research and development model typical of early-stage biotech firms, where substantial upfront investment is required for drug development with the expectation of future revenue once products reach market approval. The company's future revenue model will likely be based on product sales and licensing agreements once ALRN-6924 or other pipeline candidates receive regulatory approval. In the pharmaceutical industry, companies typically generate revenue through direct sales to hospitals, clinics, and pharmacies, as well as through licensing deals with larger pharmaceutical companies for commercialization rights in specific geographic regions. Several factors could significantly impact Rein Therapeutics' future profitability margins. Positive factors include the potential for premium pricing given the precision medicine approach and unmet medical need in wild-type p53 cancers, possible orphan drug designations that provide market exclusivity, and the relatively large addressable market since approximately half of all cancers retain functional p53. Negative factors include intense competition from other oncology companies developing p53-targeting therapies, the high costs associated with clinical trials and regulatory approval processes, potential manufacturing complexities for cell-permeating peptides, and the inherent risks of clinical trial failures that could eliminate revenue potential entirely. The company's current cash burn rate of approximately $22 million annually means it must either secure additional funding through equity raises or partnerships, or achieve clinical milestones that attract strategic investors or licensing partners.
Competitive moat
Rein Therapeutics operates in a highly competitive landscape with limited sustainable competitive advantages at this stage of development. The company's primary potential moat lies in its specialized expertise in cell-permeating peptide technology and its specific approach to p53 pathway reactivation. The scientific team's deep knowledge in this area, particularly given the founders' academic backgrounds, provides some technical differentiation. However, this moat is relatively narrow and vulnerable to competition. Several factors limit the strength of Rein's competitive position. The p53 pathway is a well-known target in oncology, with multiple large pharmaceutical companies and biotech firms developing competing approaches, including small molecule inhibitors, other peptide-based therapies, and novel drug delivery mechanisms. The company's intellectual property portfolio, while important, operates in a crowded field where patent protection may be challenged or circumvented through alternative molecular approaches. The most significant competitive threats come from well-funded competitors with greater resources for clinical development, including companies like Amgen, Roche, and other major pharmaceutical firms that have p53-targeted programs. Additionally, the emergence of new therapeutic modalities such as protein degradation technologies (PROTACs) and advanced gene therapies could potentially offer superior efficacy or safety profiles. Rein's competitive advantage will ultimately depend on clinical trial results demonstrating superior efficacy, safety, or convenience compared to existing and emerging alternatives. Without strong clinical differentiation, the company faces the risk of becoming a "me-too" player in a crowded therapeutic space, which would significantly limit pricing power and market share potential.
Risks & safety
Rein Therapeutics presents significant financial risks typical of clinical-stage biotech companies, with limited margin of safety for investors. • Cash position and burn rate: The company holds $12.9 million in cash as of Q4 2024, with an annual cash burn of approximately $22 million, providing less than 7 months of runway at current spending levels • Debt and solvency: Minimal debt with debt-to-equity ratio near zero, but faces immediate funding needs to continue operations • Valuation metrics: Extremely volatile ratios due to losses and low market cap of $44 million; negative earnings make traditional P/E ratios meaningless • Operating losses: Consistent quarterly losses ranging from $6-9 million, with full-year 2024 net loss of $63 million • Revenue generation: Zero revenue across all periods, entirely dependent on successful clinical development and future commercialization • Going concern risk: Immediate need for additional financing through equity raises, debt, or strategic partnerships to avoid potential bankruptcy The margin of safety is essentially nonexistent from a traditional value investing perspective, as the company trades primarily on speculative potential rather than tangible assets or cash flows.
Recent development
Based on available financial data, Rein Therapeutics has maintained focus on its core ALRN-6924 program while managing the typical challenges of clinical-stage drug development. The company's financial statements show consistent investment in research and development activities, with operating cash flow losses reflecting ongoing clinical trial expenses and regulatory activities. Key strategic considerations evident from the financial trajectory include the company's need to secure additional funding, as demonstrated by the declining cash position from $21.9 million in Q2 2024 to $12.9 million by year-end. This cash burn pattern suggests the company has been actively advancing its clinical programs while also indicating the urgent need for either successful clinical milestones that could attract partnership opportunities or additional equity financing. The company's asset base has fluctuated significantly, suggesting possible strategic transactions or accounting adjustments related to clinical trial activities. The maintenance of minimal debt levels indicates management's preference for equity financing over debt, which is typical for biotech companies without revenue-generating assets to secure borrowings. Without detailed earnings call transcripts, the specific strategic pivots and clinical milestones are not fully visible, but the financial patterns suggest continued investment in the core p53 reactivation platform while managing the inherent funding challenges of clinical-stage biopharmaceutical development.
RNTX company profile · for informational purposes only — not investment advice.
Track RNTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free